E. R. Agamian
E. R. Agamian has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Anna S. Derbeneva
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
3 shared publications - Anzhella Zh. Fursova
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
3 shared publications - I. F. Nikulich
Novosibirsk Regional Clinical Hospita; Novosibirsk State Medical University
3 shared publications - I. M. Amir
State Novosibirsk Regional Clinical Hospital
3 shared publications - M. S. Tarasov
Novosibirsk Regional Clinical Hospita; Novosibirsk State Medical University
3 shared publications - Maria A. Vasilyeva
Novosibirsk Regional Clinical Hospital; Novosibirsk State Medical University
3 shared publications
Latest Publications
- 16 October 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (5)
Subretinal fibrosis in neovascular age-related macular degeneration: risk factors, mechanisms of development, and current options for prevention and treatment
The results of numerous randomized clinical trials and clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of the neovascular complex in neovascular age-related macular degeneration (nAMD). At the same time, a reduction in the risk of macular fibrosis has been demonstrated, with its incidence decreasing from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% during anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, timing of treatment initiation, treatment regimen and regularity, and type of drug. Fluctuations in retinal thickness and volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and hinder complete restoration of ellipsoid zone integrity. Extensive investigation of the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with production of TGF-β and CTGF, as well as cross-talk with classical fibrotic pathways. The synergistic action of Ang-2 and VEGF-A promotes subretinal scarring and underscores the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may sustain tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema, but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as evidenced by a significant reduction in SHRM volume — a key precursor of fibrotic changes.
- 16 October 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (5)
Subretinal fibrosis in neovascular age-related macular degeneration: risk factors, mechanisms of development, and current options for prevention and treatment
The results of numerous randomized clinical trials and clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of the neovascular complex in neovascular age-related macular degeneration (nAMD). At the same time, a reduction in the risk of macular fibrosis has been demonstrated, with its incidence decreasing from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% during anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, timing of treatment initiation, treatment regimen and regularity, and type of drug. Fluctuations in retinal thickness and volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and hinder complete restoration of ellipsoid zone integrity. Extensive investigation of the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with production of TGF-β and CTGF, as well as cross-talk with classical fibrotic pathways. The synergistic action of Ang-2 and VEGF-A promotes subretinal scarring and underscores the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may sustain tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema, but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as evidenced by a significant reduction in SHRM volume — a key precursor of fibrotic changes.
- Open Access
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 573-582
Hyperreflective Focuses as a Biomarker of Optical Coherence Tomography in Retinal Diseases: Pathogenesis, Visualization, and Clinical Significance
The presented literature review is devoted to an important OCT biomarker of retinal diseases; hyperreflective foci (GRF); which are considered as a promising indicator of inflammatory processes and vascular disorders of the retina. The purpose is to clarify modern ideas about the nature and classification of hyperreflective foci as an important diagnostic marker. This is necessary to improve the accuracy of diagnosis and monitoring of the most common retinal diseases; as well as to develop personalized treatment approaches; including using artificial intelligence technologies in ophthalmology. GRFs are defined as discrete point or rounded structures with increased optical density; ranging in size from 20 to 100 microns; localized within the retinal layers or in the subretinal space. GRF is not a specific morphological feature; but a universal phenotype reflecting a wide range of pathophysiological processes. The article describes in detail the morphology of foci; the pathogenetic mechanisms of their formation; the prognostic role and differences in age-related macular degeneration; diabetic retinopathy; diabetic macular edema. The correct differential interpretation of GRF requires an integrated approach; including an analysis of medical history and risk factors; a detailed assessment of their localization and morphological characteristics; as well as consideration of concomitant OCT signs and multimodal imaging data. The integration of these parameters makes it possible to accurately determine the nature of hyperreflective foci; choose the optimal patient management tactics; and reasonably predict the course of the disease.
- 5 October 2026
- Published by PE Polunina Elizareta Gennadievna in Ophthalmology in Russia
- Vol. 23 (3) , 573-582
Open AccessHyperreflective Focuses as a Biomarker of Optical Coherence Tomography in Retinal Diseases: Pathogenesis, Visualization, and Clinical Significance
The presented literature review is devoted to an important OCT biomarker of retinal diseases; hyperreflective foci (GRF); which are considered as a promising indicator of inflammatory processes and vascular disorders of the retina. The purpose is to clarify modern ideas about the nature and classification of hyperreflective foci as an important diagnostic marker. This is necessary to improve the accuracy of diagnosis and monitoring of the most common retinal diseases; as well as to develop personalized treatment approaches; including using artificial intelligence technologies in ophthalmology. GRFs are defined as discrete point or rounded structures with increased optical density; ranging in size from 20 to 100 microns; localized within the retinal layers or in the subretinal space. GRF is not a specific morphological feature; but a universal phenotype reflecting a wide range of pathophysiological processes. The article describes in detail the morphology of foci; the pathogenetic mechanisms of their formation; the prognostic role and differences in age-related macular degeneration; diabetic retinopathy; diabetic macular edema. The correct differential interpretation of GRF requires an integrated approach; including an analysis of medical history and risk factors; a detailed assessment of their localization and morphological characteristics; as well as consideration of concomitant OCT signs and multimodal imaging data. The integration of these parameters makes it possible to accurately determine the nature of hyperreflective foci; choose the optimal patient management tactics; and reasonably predict the course of the disease.
- 18 August 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (4) , 120-126
The effect of angiogenesis inhibitor therapy on the risk of fibrosis formation in neovascular age-related macular degeneration and potential strategies for its prevention
Numerous randomized clinical trials and real-world clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of neovascular complexes in neovascular age-related macular degeneration (nAMD), with a proven reduction in the risk of macular fibrosis, the incidence of which decreased from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% after introduction of anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, time of therapy initiation, treatment regimen, its regularity, and the type of drug. Variations in retinal thickness and the volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and prevent full restoration of the integrity of the ellipsoid zone. Extensive research into the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with the production of TGF-β and CTGF, and cross-talk with classical fibrotic pathways. The synergism between Ang-2 and VEGF-A stimulates subretinal scarring and highlights the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may support tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as confirmed by a significant reduction in the volume of SHRM — a key precursor to fibrotic changes.
- 18 August 2026
- Published by Media Sphere Publishing Group in Russian Annals of Ophthalmology
- Vol. 142 (4) , 120-126
The effect of angiogenesis inhibitor therapy on the risk of fibrosis formation in neovascular age-related macular degeneration and potential strategies for its prevention
Numerous randomized clinical trials and real-world clinical practice have demonstrated the effect of angiogenesis inhibitors (anti-VEGF agents) on the activity and growth of neovascular complexes in neovascular age-related macular degeneration (nAMD), with a proven reduction in the risk of macular fibrosis, the incidence of which decreased from 39—100% in the “pre-antiangiogenic era” to 20.4—61.4% after introduction of anti-VEGF therapy. The main factors determining the risk of subretinal fibrosis are disease activity, time of therapy initiation, treatment regimen, its regularity, and the type of drug. Variations in retinal thickness and the volatility of specific fluid compartments lead to an increase in the volume of subretinal hyperreflective material (SHRM) and prevent full restoration of the integrity of the ellipsoid zone. Extensive research into the role of angiopoietin-2 (Ang-2) in the development of fibrosis has shown that it acts not only as a cofactor of angiogenesis but also as an independent regulator of fibrogenesis through vascular destabilization with increased VEGF-mediated permeability and exudation, activation of macrophages and microglia with the production of TGF-β and CTGF, and cross-talk with classical fibrotic pathways. The synergism between Ang-2 and VEGF-A stimulates subretinal scarring and highlights the high potential of bispecific therapy for improving clinical outcomes in patients with nAMD. Compensatory activation of Ang-2 during anti-VEGF monotherapy may support tissue remodeling, contributing to the development of treatment resistance. Preclinical studies in models of choroidal neovascularization and clinical data on the effectiveness of faricimab 6 mg through dual Ang-2/VEGF-A inhibition have demonstrated not only superiority in controlling exudation and resolving retinal edema but also a targeted effect on preventing proliferation and the development of subretinal fibrosis, as confirmed by a significant reduction in the volume of SHRM — a key precursor to fibrotic changes.